Expert Approaches to the Assessment of Losartan Drugs Bioequivalence
Angiotensin II receptor antagonists (ARAs) are one of the most promising classes of antihypertensive drugs. They are most widely represented on the Russian market by losartan drugs which total 24 items. Therefore, it is crucial to analyse the factors that may affect the results of comparison of gene...
Main Authors: | D. P. Romodanovsky, D. V. Goryachev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
NEICON ISP LLC
2020-02-01
|
Series: | Ведомости Научного центра экспертизы средств медицинского применения |
Subjects: | |
Online Access: | https://www.vedomostincesmp.ru/jour/article/view/270 |
Similar Items
-
Highly variable medicines - specific aspects of bioequivalence studies
by: D. P. Romodanovsky, et al.
Published: (2018-02-01) -
Planning Bioequivalence Studies in the Context of the COVID-19 Pandemic
by: D. P. Romodanovsky, et al.
Published: (2021-03-01) -
PLANNING AND EVALUATION OF BIOEQUIVALENCE STUDIES OF ATAZANAVIR PRODUCTS
by: N. E. Uvarova, et al.
Published: (2018-12-01) -
INFLUENCE OF SEX DIFFERENCES ON PHARMACOKINETICS OF DRUGS WITHIN THE FRAMEWORK OF BIOEQUIVALENCE STUDIES OF GENERIC MEDICINAL PRODUCTS
by: D. P. Romodanovsky, et al.
Published: (2018-09-01) -
Regulatory requirements of the European Medicines Agency for evaluation of bioequivalence of modified-release medicinal products
by: D. P. Romodanovsky, et al.
Published: (2019-03-01)